Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

77.47 USD +0.81 (+1.06%)
Official Closing Price Updated: 7:59 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027
Financialnewsmedia.com News Commentary 
From PR Newswire
Merck Announces First-Quarter 2021 Dividend
Merck Announces First-Quarter 2021 Dividend 
From Business Wire News Releases
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 
From Business Wire News Releases
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1
FDA Approves KEYTRUDA Plus Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10) 
From Business Wire News Releases
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
From GlobeNewswire News Releases
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Vers
KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC 
From Business Wire News Releases
Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop
Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients 
From Business Wire News Releases
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
Financialnewsmedia.com News Commentary 
From PR Newswire
Thinking about trading options or stock in General Electric, Merck, Roku, Canopy Growth Corp, or Upwork?
InvestorsObserver issues critical PriceWatch Alerts for GE, MRK, ROKU, CGC, and UPWK. 
From PR Newswire
Pappas Capital Portfolio Company VelosBio to be Acquired by Merck
Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. ("VelosBio" or the "Company"), has entered into a definitive... 
From PR Newswire
LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA12-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) 
From Business Wire News Releases
LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
LYNPARZA (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer 
From Business Wire News Releases
Merck to Acquire VelosBio
Merck to Acquire VelosBio 
From Business Wire News Releases
Animal Parasiticides Market : Facts, Figures and Analytical Insights 2020-2024
Harrisburg, NC -- (SBWIRE) -- 10/29/2020 -- The Animal Parasiticides Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from... 
From SBWire - Latest Press Releases
Merck Announces Third-Quarter 2020 Financial Results
Merck Announces Third-Quarter 2020 Financial Results 
From Business Wire News Releases
Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts
Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts 
From Business Wire News Releases
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
Financialnewsmedia.com News Commentary 
From PR Newswire
Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020
Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020 
From Business Wire News Releases
Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
Merck Announces Positive Topline Results from 2 Ph3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine 
From Business Wire News Releases
MSD Issues 2019/2020 Corporate Responsibility Report
Tags Corporate Social Responsibility Responsible Business & Employee Engagement MSD
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA
Merck Presents Three-Year Survival Data for KEYTRUDA® in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab 
From Business Wire News Releases
Orphan Drugs Market 2020 | Global Industry Overview, Sales Revenue, Demand and Opportunity 2025
Tags Health & Medicine
From AB Newswire
SPACs Surge as Biotech Booms
From InvestorBrandNetwork
SPACs Surge as Biotech Booms
NetworkNewsWire Editorial Coverage 
From PR Newswire
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
From PR Newswire
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 
From Business Wire News Releases
Merck Issues 2019/2020 Corporate Responsibility Report
Merck Issues 2019/2020 Corporate Responsibility Report 
From Business Wire News Releases
Targeted Therapies for Glioblastoma Becoming Critical As Increasing Incidence of Brain Cancer Rises
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account